DexCom Inc (DXCM)vsLENSAR Inc (LNSR)
DXCM
DexCom Inc
$78.62
+0.08%
HEALTHCARE · Cap: $32.47B
LNSR
LENSAR Inc
$5.97
+0.84%
HEALTHCARE · Cap: $74.58M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 8146% more annual revenue ($4.97B vs $60.26M). LNSR leads profitability with a 57.6% profit margin vs 20.1%. LNSR trades at a lower P/E of 33.7x. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
LNSR
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.9%
Fair Value
$676.00
Current Price
$78.62
$597.38 discount
Margin of Safety
-85.9%
Fair Value
$6.68
Current Price
$5.97
$0.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Every $100 of equity generates 36 in profit
Keeps 58 of every $100 in revenue as profit
Conservative balance sheet, low leverage
18.4% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.3x book value
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 57.6% and operating margin at 12.9%. Revenue growth of 18.4% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : LNSR
The primary concerns for LNSR are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
DXCM profiles as a mature stock while LNSR is a growth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.48 — expect wider price swings.
LNSR is growing revenue faster at 18.4% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 56/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?